AZD4017

DRUG7 trials

Sponsors

AstraZeneca, University of Birmingham, University of Leeds

Conditions

Diabetes Mellitus Type 2Diabetes Mellitus, Type 2HealthyIdiopathic Intracranial HypertensionObesityRaised Intraocular Pressure

Phase 1

Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017

CompletedNCT00791752

AstraZenecaHealthy

Start: 2008-11-30End: 2009-03-31Target: 40Updated: 2009-06-16

Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017.

CompletedNCT00799747

AstraZenecaHealthy

Start: 2008-12-31End: 2009-04-30Updated: 2009-07-02

Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses

CompletedNCT00841048

AstraZenecaDiabetes Mellitus Type 2

Start: 2009-02-28End: 2009-05-31Updated: 2009-09-30

Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue

CompletedNCT01096004

AstraZenecaObesity

Start: 2010-03-31End: 2010-05-31Updated: 2010-12-10

Phase 2

A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure

CompletedNCT01173471

AstraZenecaRaised Intraocular Pressure

Start: 2010-12-31End: 2012-11-30Updated: 2014-02-14

Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.

CompletedNCT02017444

University of BirminghamIdiopathic Intracranial Hypertension

Start: 2014-04-25End: 2016-12-19Updated: 2021-10-27

Glucocorticoids and Skin Healing in Diabetes (GC-SHealD)

CompletedNCT03313297

University of LeedsDiabetes Mellitus, Type 2

Start: 2018-04-10End: 2019-03-13Updated: 2019-03-22

Related Papers

Impact of glucocorticoids on patients’ quality of life: a qualitative study assessing face validity and feasibility of the Steroid PRO in patients with inflammatory gastroenterology, respiratory and dermatology conditions

BMJ Open2025-02-011 citations

Nuclear Magnetic Resonance Spectroscopy Metabolomics in Idiopathic Intracranial Hypertension to Identify Markers of Disease and Headache

Neurology2022-09-0821 citations

Assessing the Efficacy and Safety of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial

JMIR Research Protocols2017-09-1840 citations